Inactive Instrument

Novartis AG Stock price Xetra

Equities

NOT

CH0012005267

Pharmaceuticals

Sales 2024 * 48.14B 44.63B Sales 2025 * 50.19B 46.53B Capitalization 211B 196B
Net income 2024 * 10.05B 9.31B Net income 2025 * 11.03B 10.23B EV / Sales 2024 * 4.63 x
Net Debt 2024 * 11.49B 10.66B Net Debt 2025 * 10.14B 9.4B EV / Sales 2025 * 4.41 x
P/E ratio 2024 *
18.6 x
P/E ratio 2025 *
16.5 x
Employees 76,057
Yield 2024 *
3.9%
Yield 2025 *
4.03%
Free-Float 81.95%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Novartis AG

Managers TitleAgeSince
Chief Executive Officer 48 04-12-31
Director of Finance/CFO 59 02-12-31
Chief Tech/Sci/R&D Officer 62 22-05-15
Members of the board TitleAgeSince
Director/Board Member 62 12-12-31
Director/Board Member 65 20-02-27
Chairman 68 12-12-31
More insiders
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock Novartis AG
  4. Stock Novartis AG - Xetra